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INTRODUCTION 
The systemic treatment of disease via transdermal route is 
not a recent innovation. But, in the last two decades, 
transdermal drug delivery has gained increasing interest. 
So, transdermal controlled drug delivery systems have been 
developed in order to avoid hepatic first-pass effect thus 
improving drug bioavailability and to overcome the side-
effects associated with oral route1,2. Transdermal drug 
delivery systems are currently available for the treatment of 
various diseases such as cardiovascular diseases, 
Parkinson’s disease, Alzheimer’s disease, depression, 
anxiety and attention deficit hyperactivity disorder 
(ADHD), skin cancer, female sexual dysfunction, post-
menopausal bone loss and urinary incontinence. The 
application of transdermal system to a wider range of drugs 
is still limited due to the significant barrier to penetration 
across the skin which is allied primarily with the outermost 
stratum corneum layer of the epidermis3. The use of lipid 
vesicles for transdermal drug delivery system for skin 
treatment has attracted increasing attention in recent years4-
6. To overcome the above problem, a novel type of highly 
deformable lipid vesicles called transfersomes has been 
reported to penetrate intact skin, if applied non 
occlusively7-8. 
Transfersomes have been defined as specially designed 
vesicular particles, consisting of at least one inner aqueous 
compartment surrounded by a lipid bilayer with 
appropriately tailored properties. Accordingly, 
transfersomes resemble lipid vesicles, liposomes, in 
morphology but, functionally, transfersomes are 
sufficiently deformable to penetrate pores much smaller 
than their own size. They are metastable, which makes the 
vesicle membrane ultraflexible, and, thus, the vesicles are 
highly deformable. Typical transfersomes are, therefore, 
characterized by at least one order of magnitude more 
elastic than conventional lipid vesicles, liposomes. 
Transfersomes for potential transdermal application, 
contain a mixture of lipids and biocompatible membrane 
softeners. This optimal mixture imparts flexibility to the 
elastic liposomal membrane and leads to the possibility of 
penetration through channels of the skin, which is opened 
by the carriers9-11.  
Nifedipine is an anti-hypertensive drug belonging to the 
class of calcium channel blockers. Although the oral route 
for nifedipine is widely accepted but it is associated with 
contraindicative manifestations such as gastrointestinal 
(GI) disturbance, first pass metabolism, less oral 
bioavailability12 etc. Transdermal delivery of nifedipine is a 
better option to overcome problems associated with its oral 
delivery. Hence, the objective of the present study was to 
design and evaluate transferosomes of nifedipine that 
would release the drug over a prolonged period of time thus 
avoiding first pass metabolism and to improve its systemic 
availability. 
MATERIALS AND METHODS 
Materials:  
Nifedipine was received as a gift sample from Anod 
Pharmaceuticals Pvt. Ltd. Soya phosphatidylcholine was 
purchased from Himedia Ltd, Mumbai. Span 80, 
Chloroform, Ethanol were purchased from S.D Fine 
chemicals Ltd. Methanol was purchased from E. Merck 
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Ltd. All reagents used in this study were of analytical 
grade. 
Methods: 
Preparation of Elastic Liposomal Formulations 
The elastic liposomes were prepared by conventional rotary 
evaporation sonication method. Different batches of elastic 
liposomes were prepared using different proportions of 
surfactant, phospholipids and drug. The accurately weighed 
amounts of phospholipids and surfactant were taken in a 
clean, dry, round-bottom flask and this lipid mixture was 
dissolved in small quantity of chloroform-methanol 
mixture. The organic solvent was removed by rotary 
evaporation under reduced pressure at 40°C. Final traces of 
solvents were removed under vacuum overnight. The 
deposited lipid film was hydrated with drug solution in 
ethanol (7 % v/v) by rotation at 60 rev/min for 1 hr. To 
prepare smaller vesicles, these were bath sonicated for 10 
min.The conventional liposomal formulation 
(Phosphatidylcholine:Cholesterol, 7: 3), that serve as a 
control for comparison in the present study, was prepared 
by the same method as described above. 
Drug Loading In Elastic Liposomal Formulations 
To determine the maximum amount of drug that could be 
added to elastic liposomal formulation, increasing amount 
of drug in concentration range of 4-12 mg was added and 
formulations were prepared and analyzed by optical 
microscope. In case of formulations prepared using 4-10 
mg of drug, no crystals were observed but formulation 
containing 12 mg of drug showed crystal formation (shown 
in fig. 1 and fig. 2). Thus, the maximum amount of drug 
that could be incorporated in elastic liposomal formulation 
was found to be 10 mg. 
 
Table 1: Drug Loading in Elastic Liposomal Formulations 
S.No. Amount of Drug (mg) Observations 
1. 4 CNA 
2. 6 CNA 
3. 8 CNA 
4. 10 CNA 
5. 12 CA 
CNA-crystals not appear ; CA-crystals appear 
 
Figure 1: Photomicrograph of Elastic Liposomal 
Formulation Containing 10 mg Drug 
 
Figure 2: Photomicrograph of Elastic Liposomal 
Formulation Containing 12 mg Drug 
Further formulations (EL-SP1 – ELSP5) were then prepared by incorporating 10 mg of drug to each containing varying 
ratio of phospholipids and surfactant. The composition of these formulations has been shown in table 1. 
Table 2: Composition of Different Elastic Liposomal Formulations 
S. No. Formulation code *Soya PC (mg) Span 80 (mg) Solvent (ml) 
Chloroform:Methanol 
1 **EL-SP1 95 5 10 5 
2 EL-SP2 90 10 10 5 
3 EL-SP3 85 15 10 5 
4 EL-SP4 80 20 10 5 
5 EL-SP5 75 25 10 5 
     *Soya PC - Phosphatidylcholine 
     **EL-SP - Elastic liposomal formulation containing different concentrations of Span80 
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CHARACTERIZATION OF ELASTIC LIPOSOMAL 
FORMULATIONS 
Vesicle Size and Size Distribution 
The vesicle size before sonication was determined by 
optical microscopy using stage eyepiece micrometer. A 
total of 100 particles per batch were counted for their size. 
After sonication the vesicle size was determined by 
dynamic light scattering method using particle size analyzer 
(Malvern, Instruments). 
Vesicle Shape 
Elastic liposomal vesicles were visualized by using 
Moragagni 268D TEM with an accelerating voltage of 100 
kV. A drop of the sample was placed onto a carbon-coated 
copper grid to leave a thin film on the grid. The grid was 
allowed to air dry thoroughly and the samples were viewed 
on a transmission electron microscope.  
Vesicles without sonication were also visualized by using 
an optical microscope. A thin film of elastic liposomes was 
spread on a slide and after placing cover slip it was 
observed under the optical microscope14. 
Entrapment Efficiency 
For determination of entrapment efficiency, the excess 
amount of unentrapped drug was separated by the use of 
the minicolumn centrifugation method.. 
 
Percentage entrapment  =     Entrapped drug (µg) × 100 
                                 Total drug added (μg) 
Number of Vesicles Per Cubic mm 
Elastic liposomal formulation (without sonication) diluted 
five times with 0.9 % w/v sodium chloride solution and 
number of elastic liposomes per cubic mm was counted by 
optical microscopy using haemocytometer by following 
formula- 
Total number of transferosomes per cubic mm =  
                        Counted × dilution factor × 4000                                                  
                        Total number of squares counted 
 
Drug Release Study through Cellophane Membrane 
The in vitro drug release study was carried out in modified 
Diffusion cell using Dialysis membrane (Himedia 
laboratories Pvt Ltd: dry, unwashed, open ended; flat 
width: 28.46mm; inflated diameter: 17.5mm; Length: 1m). 
The membrane was soaked in PBS pH 6.8 for 9-12 hrs and 
it was clamped carefully to one end of the hollow glass 
tube of dialysis cell (2.3 cm diameter; 4-16 cm2 area). Then 
transferosomal gel (which was prepared by using 1% w/v 
carbopol 934 in distilled water) was spread uniformly on 
the dialysis membrane. 50 ml of PBS pH 6.8 was taken in a 
beaker, which was used as receptor compartment. The 
donor compartment was kept in contact with the receptor 
compartment. This whole assembly was kept on a magnetic 
stirrer and the solution on the receptor side was stirred 
continuously using a magnetic bead. The temperature of the 
cell was maintained at 37°C. Sample (5 ml) was withdrawn 
at suitable time intervals and replaced with equal amounts 
of fresh dissolution media. Samples were analysed 
spectrophotometrically at 330 nm and the cumulative % 
drug release was calculated. The difference between the 
readings of drug release and control was used as the actual 
reading in each case. 
Ex-vivo Skin Permeation Study 
The ex vivo skin permeation study was carried out in a 
modified Diffusion cell, using rat skin. A section of skin 
was cut, cleaned and clamped carefully to one end of the 
hollow glass tube of dialysis cell (2.3 cm diameter; 4-16 
cm2 area) keeping the dorsal side upward.  Then 
transferosomal gel (which was prepared by using 1% w/v 
carbopol 934 in distilled water) was spread uniformly on 
the skin. PBS pH 6.8 was used as dissolution media. The 
donor compartment was kept in contact with receptor 
compartment. This whole assembly was kept on a magnetic 
stirrer and the solution on the receptor side was stirred 
continuously using a magnetic bead and temperature of the 
cell was maintained at 37°C. Sample (5 ml) was withdrawn 
at suitable time intervals and replaced with equal amounts 
of fresh dissolution media. Samples were analyzed 
spectrophotometrically at 330 nm and the cumulative % 
drug permeated across skin was calculated. 
Stability Study  
Stability is technically defined as the capacity of particular 
formulation in a specific container/closure system to 
remain within its physical, chemical, microbiological, 
therapeutic and toxicological specification. The optimized 
elastic liposomal formulations were stored in glass vials at 
room temperature and in refrigerator (4±2oC) for 60 days. 
Formulations were evaluated after every 20 days for 
various physicochemical parameters15-16. 
RESULTS AND DISCUSSION 
The conventional rotary evaporation sonication method was 
used to prepare the transfersomal formulation. Vesicles size 
and size distribution was determine by optical 
microscope(less than 1000nm) shown in fig - 3. 
To determine the vesicle shape Transmission Electron 
Microscopic (TEM) study was carried out which reveals 
the mechanism of skin permeation of elastic liposomes. As 
shown in Table- 3, the maximum entrapment efficiency 
obtained was 67.53±1.6 for transferosomal formulation EL-
SP3. It was observed that with increase in surfactant 
concentration, entrapment efficiency increased but up to a 
certain concentration only (EL-SP3), after that it started 
decreasing. This may due to the possible coexistence of 
mixed micelles and vesicles at higher concentration of 
surfactant resulting in lower drug entrapment in mixed 
micelles. Similar trend was observed in the number of 
vesicles and the maximum number obtained was 51.13±1.6 
for transfersomal formulation of EL-SP3. 
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Figure 3: Vesicle Size Distribution of EL-SP3 
Table 3: Characterization of Transfersomal Formulations 
Formulation Code Entrapment Efficiency Number of Vesicles 
**EL-SP1 49.46±1.5 46.02±1.1 
EL-SP2 53.96±1.3 47.90±1.4 
EL-SP3 67.53±1.6 51.13±1.6 
EL-SP4 60.40±1.1 43.81±1.2 
EL-SP5 58.22±1.0 44.76±1.1 
Liposomes 62.30±1.1 49.25±0.6 
*Soy PC = Phosphatidylcholine 
**EL-SP = Elastic liposomal formulation containing different concentrations of Span80 
 
Formulation EL-SP3 was subjected to in vitro drug release 
studies using cellophane membrane. After 24hrs nifedipine 
release from elastic liposomes was 70.42±0.7. This clearly 
indicated sustained release of nifedipine from elastic 
liposomal formulations. The mathematical models were 
used to evaluate the kinetics and mechanism of drug release 
from elastic liposomal gel. The model that best fits the 
release data was selected based on the correlation 
coefficient (r2) value. According to data the value of r2 for 
zero order model was found to be higher than that of 
higuchi and first order model. So, the EL-SP3 formulation 
confirmed to show sustained zero order release. In case of 
korsermeyer peppas the value of n found to be 0.576 i.e. the 
drug follows non-fickian diffusion (0.45<n<0.89). 
The ex vivo skin permeation study was carried out in a 
modified Diffusion cell, using rat skin for each EL-SP3 
formulation and liposomes. The value of transdermal flux 
for EL-SP3 observed was 76.41±0.9. This was higher than 
that obtained from liposome which was 71.44±0.9. These 
results indicated that the more amount of drug permeated 
through skin by elastic liposomes as compared to 
liposomes. 
Table 4: % Ex-vivo Skin Permeation study 
S.No. Time (hr) 
Elastic Liposomes 
(EL-SP3) 
Liposomes 
1. 0 0 0 
2. 1 8.62±0.6 6.51±1.0 
3. 2 13.17±1.7 7.2±1.5 
4. 3 17.68±1.8 8.57±1.0 
5. 4 23.67±1.5 11.52±0.9 
6. 5 25.25±1.4 13.74±1.0 
7. 6 30.02±6.2 16.65±1.1 
8. 7 29.9±6.6 26.33±1.1 
9. 8 35.61±1.0 27.81±0.9 
10. 9 38.76±1.0 31.3±0.8 
11. 10 41.54±0.9 32.66±0.8 
12. 12 45.86±1.4 39.37±0.8 
13. 16 54.71±1.8 48.92±1.1 
14. 20 67.57±0.7 60.50±0.1 
15. 24 76.41±0.9 71.44±0.9 
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Figure 4: % Drug release of Nifedipine across skin  
Table 5: Regression analysis of release data based on best curve-fitting method for EL-SP3 formulation  
Formulation Zero order First order Higuchi Korsemeyer Peppas 
 N R
2 
n R
2 
N R
2 
N R
2 
EL-SP3 5.732 0.991 2.009 0.988 11.48 0.989 0.576 0.885 
           
STABILITY STUDY 
Table 6: Visual and Microscopic Appearance of Elastic Liposomal Formulations after Storage 
Parameteres  Time (in days)    Room Temp/ Refrigrated Temp. Observations 
Consistency of liposomal 
formulations 
20 
20 
40 
40 
60 
60 
(1) 
(2) 
(1) 
(2) 
(1) 
(2) 
No Change 
No Change 
No Change 
No Change 
Increased 
Increased 
Appearance of drug crystals 20 
20 
40 
40 
60 
60 
(1) 
(2) 
(1) 
(2) 
(1) 
(2) 
Not appeared 
Not appeared 
Not appeared 
Not appeared 
Not appeared 
Not appeared 
1. Room temperature  2. Refrigerated temperature (4±2
o
C) 
 
Figure 5: Effect of Storage Temperature on Vesicle Size 
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Table 7: Effect of Storage Temperature on Vesicle Size 
Parameters Time (in days) Storage temperature Observation 
 
 
 
 
Vesicle size (µm) 
20 
20 
40 
40 
60 
60 
               1 
               2 
               1 
               2 
               1 
                2 
6.0±1.9 
6.8±1.2 
6.6±1.7 
7.6±1.8 
6.7±0.9 
7.8±2.6 
1. Data are represent of mean ± SD (n=3) 
1. Room temperature 2.Refrigerated temperature (4±2
o
c) 
Effect of storage temperature on morphology 
The formulations were observed in glass vials for a period 
of 2 months and were observed at definitive intervals 
visually and under optical microscope for change in 
consistency and appearance of drug crystals. Results are 
shown in Table 6. 
Effect of storage temperature on size and size 
distribution 
Elastic liposomal formulations were also characterized for 
size at regular interval time intervals for the period of two 
months. Results are recorded in Table-7 and shown 
graphically in Fig - 5. 
CONCLUSION 
The results of the present study showed that Transdermal 
delivery can maintain a suitable plasma concentration 
through a noninvasive zero-order delivery, which would 
enhance the efficacy and improve the permeability of 
nifedipine. Thus, deformable lipid vesicles, transfersomes, 
are better alternative as a drug delivery system for 
nifedipine over oral route because of avoidance of first pass 
metabolism thus leading to improved bioavailability of 
drug and rapid termination of drug input. It creates a new 
opportunity for the well-controlled transdermal delivery of 
a number of drugs that have a problem of administration by 
other routes.  
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